Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy

Ahmed Magheli, Soroush Rais-Bahrami, Hugh J. Peck, Patrick C. Walsh, Jonathan I. Epstein, Bruce J. Trock, Mark L Gonzalgo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: We investigated the effect of tumor location (anterior vs posterior) on pathological characteristics and biochemical-free survival in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml undergoing radical prostatectomy since transition zone tumors are known to present with higher prostate specific antigen levels. Materials and Methods: We retrospectively studied the records of 265 patients treated with radical prostatectomy between 1984 and 2005 who had preoperative prostate specific antigen levels greater than 20 ng/ml. Review of pathology reports was performed and tumor location (anterior vs posterior) was defined. Differences in clinicopathological characteristics and prostate specific antigen recurrence rates were examined. Results: Of 265 patients with a preoperative prostate specific antigen level of greater than 20 ng/ml who underwent radical prostatectomy 50 (19%) had anterior tumors and 215 (81%) had posterior tumors. Patients with anterior tumors had lower clinical stage and less seminal vesicle involvement than patients with posterior tumors (p = 0.006 and <0.001, respectively). Although Kaplan-Meier analysis demonstrated significantly higher rates of 5-year biochemical recurrence-free survival for patients with anterior vs posterior tumors (63% vs 40%, p = 0.020), anterior tumor location was not an independent predictor of biochemical recurrence. Conclusions: Radical prostatectomy is a feasible treatment option in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml. The 5-year biochemical-free survival rate was 47%. Although anterior tumor location was associated with favorable pathological features and improved biochemical-free survival, it was not an independent predictor of biochemical recurrence. Further studies are warranted to identify patients with high preoperative prostate specific antigen levels most likely to have recurrence.

Original languageEnglish (US)
Pages (from-to)1311-1315
Number of pages5
JournalJournal of Urology
Volume178
Issue number4
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Neoplasms
Recurrence
Survival
Seminal Vesicles
Kaplan-Meier Estimate
Survival Rate
Pathology

Keywords

  • local
  • neoplasm recurrence
  • prostate
  • prostate-specific antigen
  • prostatectomy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy. / Magheli, Ahmed; Rais-Bahrami, Soroush; Peck, Hugh J.; Walsh, Patrick C.; Epstein, Jonathan I.; Trock, Bruce J.; Gonzalgo, Mark L.

In: Journal of Urology, Vol. 178, No. 4, 10.2007, p. 1311-1315.

Research output: Contribution to journalArticle

Magheli, Ahmed ; Rais-Bahrami, Soroush ; Peck, Hugh J. ; Walsh, Patrick C. ; Epstein, Jonathan I. ; Trock, Bruce J. ; Gonzalgo, Mark L. / Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy. In: Journal of Urology. 2007 ; Vol. 178, No. 4. pp. 1311-1315.
@article{c3789ca602ca4ca690f5ebce09442001,
title = "Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy",
abstract = "Purpose: We investigated the effect of tumor location (anterior vs posterior) on pathological characteristics and biochemical-free survival in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml undergoing radical prostatectomy since transition zone tumors are known to present with higher prostate specific antigen levels. Materials and Methods: We retrospectively studied the records of 265 patients treated with radical prostatectomy between 1984 and 2005 who had preoperative prostate specific antigen levels greater than 20 ng/ml. Review of pathology reports was performed and tumor location (anterior vs posterior) was defined. Differences in clinicopathological characteristics and prostate specific antigen recurrence rates were examined. Results: Of 265 patients with a preoperative prostate specific antigen level of greater than 20 ng/ml who underwent radical prostatectomy 50 (19{\%}) had anterior tumors and 215 (81{\%}) had posterior tumors. Patients with anterior tumors had lower clinical stage and less seminal vesicle involvement than patients with posterior tumors (p = 0.006 and <0.001, respectively). Although Kaplan-Meier analysis demonstrated significantly higher rates of 5-year biochemical recurrence-free survival for patients with anterior vs posterior tumors (63{\%} vs 40{\%}, p = 0.020), anterior tumor location was not an independent predictor of biochemical recurrence. Conclusions: Radical prostatectomy is a feasible treatment option in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml. The 5-year biochemical-free survival rate was 47{\%}. Although anterior tumor location was associated with favorable pathological features and improved biochemical-free survival, it was not an independent predictor of biochemical recurrence. Further studies are warranted to identify patients with high preoperative prostate specific antigen levels most likely to have recurrence.",
keywords = "local, neoplasm recurrence, prostate, prostate-specific antigen, prostatectomy, prostatic neoplasms",
author = "Ahmed Magheli and Soroush Rais-Bahrami and Peck, {Hugh J.} and Walsh, {Patrick C.} and Epstein, {Jonathan I.} and Trock, {Bruce J.} and Gonzalgo, {Mark L}",
year = "2007",
month = "10",
doi = "10.1016/j.juro.2007.05.143",
language = "English (US)",
volume = "178",
pages = "1311--1315",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Importance of Tumor Location in Patients With High Preoperative Prostate Specific Antigen Levels (Greater Than 20 ng/ml) Treated With Radical Prostatectomy

AU - Magheli, Ahmed

AU - Rais-Bahrami, Soroush

AU - Peck, Hugh J.

AU - Walsh, Patrick C.

AU - Epstein, Jonathan I.

AU - Trock, Bruce J.

AU - Gonzalgo, Mark L

PY - 2007/10

Y1 - 2007/10

N2 - Purpose: We investigated the effect of tumor location (anterior vs posterior) on pathological characteristics and biochemical-free survival in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml undergoing radical prostatectomy since transition zone tumors are known to present with higher prostate specific antigen levels. Materials and Methods: We retrospectively studied the records of 265 patients treated with radical prostatectomy between 1984 and 2005 who had preoperative prostate specific antigen levels greater than 20 ng/ml. Review of pathology reports was performed and tumor location (anterior vs posterior) was defined. Differences in clinicopathological characteristics and prostate specific antigen recurrence rates were examined. Results: Of 265 patients with a preoperative prostate specific antigen level of greater than 20 ng/ml who underwent radical prostatectomy 50 (19%) had anterior tumors and 215 (81%) had posterior tumors. Patients with anterior tumors had lower clinical stage and less seminal vesicle involvement than patients with posterior tumors (p = 0.006 and <0.001, respectively). Although Kaplan-Meier analysis demonstrated significantly higher rates of 5-year biochemical recurrence-free survival for patients with anterior vs posterior tumors (63% vs 40%, p = 0.020), anterior tumor location was not an independent predictor of biochemical recurrence. Conclusions: Radical prostatectomy is a feasible treatment option in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml. The 5-year biochemical-free survival rate was 47%. Although anterior tumor location was associated with favorable pathological features and improved biochemical-free survival, it was not an independent predictor of biochemical recurrence. Further studies are warranted to identify patients with high preoperative prostate specific antigen levels most likely to have recurrence.

AB - Purpose: We investigated the effect of tumor location (anterior vs posterior) on pathological characteristics and biochemical-free survival in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml undergoing radical prostatectomy since transition zone tumors are known to present with higher prostate specific antigen levels. Materials and Methods: We retrospectively studied the records of 265 patients treated with radical prostatectomy between 1984 and 2005 who had preoperative prostate specific antigen levels greater than 20 ng/ml. Review of pathology reports was performed and tumor location (anterior vs posterior) was defined. Differences in clinicopathological characteristics and prostate specific antigen recurrence rates were examined. Results: Of 265 patients with a preoperative prostate specific antigen level of greater than 20 ng/ml who underwent radical prostatectomy 50 (19%) had anterior tumors and 215 (81%) had posterior tumors. Patients with anterior tumors had lower clinical stage and less seminal vesicle involvement than patients with posterior tumors (p = 0.006 and <0.001, respectively). Although Kaplan-Meier analysis demonstrated significantly higher rates of 5-year biochemical recurrence-free survival for patients with anterior vs posterior tumors (63% vs 40%, p = 0.020), anterior tumor location was not an independent predictor of biochemical recurrence. Conclusions: Radical prostatectomy is a feasible treatment option in patients with a preoperative prostate specific antigen level of greater than 20 ng/ml. The 5-year biochemical-free survival rate was 47%. Although anterior tumor location was associated with favorable pathological features and improved biochemical-free survival, it was not an independent predictor of biochemical recurrence. Further studies are warranted to identify patients with high preoperative prostate specific antigen levels most likely to have recurrence.

KW - local

KW - neoplasm recurrence

KW - prostate

KW - prostate-specific antigen

KW - prostatectomy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=34548410450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548410450&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.05.143

DO - 10.1016/j.juro.2007.05.143

M3 - Article

C2 - 17698095

AN - SCOPUS:34548410450

VL - 178

SP - 1311

EP - 1315

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -